eldisine 5mg powder for solution for injection vials
genus pharmaceuticals ltd - vindesine sulfate - powder for solution for injection - 5mg
eldisine 5 mg inj. sol. (pwdr.) i.v. vial
eg sa-nv - vindesine sulfate 5 mg - powder for solution for injection - 5 mg - vindesine sulfate 5 mg - vindesine
eldisine vindesine sulfate 5mg powder for injection vial
aspen pharmacare australia pty ltd - vindesine sulfate, quantity: 5 mg - injection, powder for - excipient ingredients: mannitol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) eldisine is indicated in the palliative treatment of the following: acute lymphocytic leukaemia of childhood resistant to other agents. blastic crises of chronic myeloid leukaemia in adults. non-small cell lung cancer. it should be noted that eldisine is usually given in combination with other oncolytic agents.
eldisine inj 5mg/2ml powder for solution
eli lilly canada inc - vindesine sulfate - powder for solution - 5mg - vindesine sulfate 5mg - antineoplastic agents
eldisine
eli lilly and company (nz) limited - vindesine sulfate 5mg; - powder for injection - 5 mg - active: vindesine sulfate 5mg
eldesine 4 milligram
eli lilly and company limited - vindesine sulphate - 4 milligram
eldesine withdrawn form 10 milligram
eli lilly and company limited - vindesine sulphate - withdrawn form - 10 milligram
eldesine 1 milligram
eli lilly and company limited - vindesine sulphate - 1 milligram
eldisine withdrawn form 5 milligram
eli lilly and company limited - vindesine sulphate - withdrawn form - 5 milligram
eldisine 5mg vial+solvent 5ml powder and solvent for solution for infusion
eli lilly and company - vindesine - powder and solvent for solution for infusion - 5 mg